BMS-986421
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 13, 2023
A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=46 | Terminated | Sponsor: Bristol-Myers Squibb | N=80 ➔ 46 | Recruiting ➔ Terminated; Adverse change in the risk/benefit.
Enrollment change • Trial termination
1 to 1
Of
1
Go to page
1